166 related articles for article (PubMed ID: 38726002)
1. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
[TBL] [Abstract][Full Text] [Related]
2. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
4. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
5. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
6. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
8. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract][Full Text] [Related]
9. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
10. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
11. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
13. The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma.
Wang Z; Zhao Y; Wo Y; Peng Y; Hu W; Wu Z; Liu P; Shang Y; Liu C; Chen X; Huang K; Chen Y; Hong H; Li F; Sun Y
Cancer Lett; 2024 Jul; 593():216951. PubMed ID: 38734159
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
16. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
17. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
[TBL] [Abstract][Full Text] [Related]
18.
Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
[TBL] [Abstract][Full Text] [Related]
19. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
20. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
